Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Eric Forman changed role as Vice President and Chief Operating Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
Action
promoted
Role
Vice President and Chief Operating Officer
Exact text from the filing
Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.
LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Reduced the quorum for stockholder meetings from a majority to 33-1/3% of voting power (effective 2022-11-06).
Change
bylaw amendment
Effective
2022-11-06
Exact text from the filing
On November 6, 2022, the Board of Directors of the Company approved Amended and Restated Bylaws. The amendment to the Bylaws was solely in respect to Section 2.8 to reduce the quorum for the transaction of business and all meetings of the stockholders from the holders of a majority to 33-1/3% of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.